Key US Patents for Canakinumab (Ilaris)
Canakinumab, marketed as Ilaris by Novartis, has multiple patents listed in the FDA's Orange Book. The primary composition-of-matter patent, US 7,829,093 (covering the human anti-IL-1β monoclonal antibody), expires on September 22, 2030.[1][2]
Other key patents extend protection:
- US 8,119,141 (methods of use for CAPS and other autoinflammatory conditions): September 22, 2030.
- US 8,420,089 (crystalline forms): November 23, 2027.
- US 10,093,719 (formulations for subcutaneous use): September 22, 2030.[2]
Pediatric exclusivity adds six months to these dates, pushing the main ones to March 22, 2031.[1]
When Do Biosimilars Enter the Market?
Biosimilar entry depends on FDA approval and patent settlements. No biosimilars are approved yet, but challenges are underway. The '093 patent faces inter partes review (IPR) petitions, with potential invalidation risks. Market entry could occur post-2030 if no further extensions or litigation delays apply, though Novartis has formulation patents lasting into the 2030s.[1][2][3]
International Patent Expirations
- Europe (EP1976860): Expires December 21, 2027, with supplementary protection certificate (SPC) extensions varying by country (e.g., up to 2032 in some).[2]
- Japan: Key patent JP2008503536 expires around 2027.[2]
Factors That Could Delay Generic/Biosimilar Competition
Novartis holds over 20 Orange Book patents for Ilaris, including process and method claims expiring 2034-2038. Ongoing Paragraph IV challenges from biosimilar developers like Samsung Bioepis and Fresenius Kabi could lead to settlements delaying entry to 2032 or later. No 505(b)(2) generics are listed.[1][2]
Who Makes Canakinumab and Sales Impact
Novartis manufactures and sells Ilaris globally, with 2023 sales over $800 million, mainly for rare autoinflammatory diseases like CAPS and TRAPS. Patent expiry risks eroding this revenue, similar to other biologics.[3]
[1]: FDA Orange Book for Ilaris
[2]: DrugPatentWatch.com - Ilaris Patents
[3]: Novartis Annual Report 2023